Polyphor – executive interview

Polyphor – executive interview

Polyphor is a development-stage company focused on oncology and antibiotics. Its lead programme is balixafortide, a CXCR4 inhibitor currently in Phase III for breast cancer. Data are expected in 2021. The company plans to start its Phase I programme of inhaled murepavadin to treat P. aeruginosa infections in CF patients by the year end.

In this interview, CEO Gokhan Batur provides an overview of the company’s programmes, especially balixafortide and inhaled murepavadin. He also reviews the Phase Ib data for balixafortide, as well as the design and timelines for the Phase III data expected next year.


You may also be interested in these:

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.